CAMBRIDGE, Mass— In a significant biopharmaceutical development, Novartis has officially completed the acquisition of Anthos Therapeutics, a clinical-stage company focused on cardiometabolic diseases, in a deal valued at up to $3.1 billion. The acquisition includes an upfront payment of $925 million, with additional milestone-based payments contingent on future regulatory and commercial achievements.
Anthos Therapeutics was launched in 2019 by Blackstone Life Sciences in collaboration with Novartis, and was granted exclusive global rights to develop, manufacture, and commercialize abelacimab—a promising novel Factor XI inhibitor originally discovered at Novartis.
Abelacimab is currently undergoing Phase 3 clinical trials, including the LILAC-TIMI 76 study for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Two additional Phase 3 trials, ASTER and MAGNOLIA, are evaluating its effectiveness in treating cancer-associated thrombosis. Results from these studies are expected in the latter half of 2026.
The acquisition underscores Blackstone Life Sciences’ strategy of building biotech companies around breakthrough therapies aimed at addressing unmet medical needs.
Goldman Sachs & Co. LLC acted as the lead financial advisor to Anthos Therapeutics, with Morgan Stanley & Co. LLC also serving as a financial advisor. Legal counsel was provided by Goodwin Procter LLP.
